TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 3 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $988,162 | +9.9% | 63,876 | +11.6% | 0.02% | +16.7% |
| Q2 2023 | $899,366 | -29.1% | 57,248 | -25.6% | 0.02% | -30.8% |
| Q1 2023 | $1,268,268 | +17.0% | 76,958 | +10.8% | 0.03% | +18.2% |
| Q4 2022 | $1,083,779 | +8.1% | 69,473 | -10.2% | 0.02% | +4.8% |
| Q3 2022 | $1,003,000 | +4.4% | 77,360 | +13.1% | 0.02% | +16.7% |
| Q2 2022 | $961,000 | -15.3% | 68,420 | -13.7% | 0.02% | +5.9% |
| Q1 2022 | $1,135,000 | +39.8% | 79,263 | +33.1% | 0.02% | +41.7% |
| Q4 2021 | $812,000 | -21.2% | 59,563 | -5.3% | 0.01% | -25.0% |
| Q3 2021 | $1,030,000 | +14.2% | 62,884 | +17.3% | 0.02% | +23.1% |
| Q2 2021 | $902,000 | +12.8% | 53,607 | +22.4% | 0.01% | +8.3% |
| Q1 2021 | $800,000 | +79.4% | 43,796 | +78.6% | 0.01% | +71.4% |
| Q4 2020 | $446,000 | +48.2% | 24,528 | +45.3% | 0.01% | +16.7% |
| Q3 2020 | $301,000 | +246.0% | 16,878 | +247.7% | 0.01% | +200.0% |
| Q2 2020 | $87,000 | – | 4,854 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Adelphi Capital LLP | 8,958,784 | $176,757,000 | 33.75% |
| Ovata Capital Management Ltd | 879,800 | $17,557,092,000 | 13.04% |
| Paulson & Co. | 13,244,711 | $261,318,000 | 5.64% |
| Glenview Capital Management | 30,582,721 | $603,397,000 | 5.28% |
| MIC CAPITAL PARTNERS (PUBLIC) (US) IM, LLC | 718,028 | $14,167,000 | 4.85% |
| Velanne Asset Management Ltd | 302,694 | $5,972,000 | 3.52% |
| Blackcrane Capital, LLC | 172,708 | $3,408,000 | 2.72% |
| Melqart Asset Management (UK) Ltd | 1,557,000 | $30,720,000 | 2.57% |
| GMT CAPITAL CORP | 3,345,976 | $66,016,000 | 2.55% |
| REDWOOD CAPITAL MANAGEMENT, LLC | 827,955 | $16,336,000 | 2.24% |